Portal de investigación
Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Capuozzo, Maurizio
- Ait Eldjoudi, Djedjiga
- Gualillo, Oreste
Grupos y Plataformas de I+D+i
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the major cause of chronic hepatic illness and the leading indication for liver transplantation in the future decades. NAFLD is also commonly associated with other high-incident non-communicable diseases, such as cardiovascular complications, type 2 diabetes, and chronic kidney disease. Aggravating the socio-economic impact of this complex pathology, routinely feasible diagnostic methodologies and effective drugs for NAFLD management are unavailable. The pathophysiology of NAFLD, recently defined as metabolic associated fatty liver disease (MAFLD), is correlated with abnormal adipose tissue-liver axis communication because obesity-associated white adipose tissue (WAT) inflammation and metabolic dysfunction prompt hepatic insulin resistance (IR), lipid accumulation (steatosis), non-alcoholic steatohepatitis (NASH), and fibrosis. Accumulating evidence links adipokines, cytokine-like hormones secreted by adipose tissue that have immunometabolic activity, with NAFLD pathogenesis and progression; however, much uncertainty still exists. Here, the current knowledge on the roles of leptin, adiponectin, ghrelin, resistin, retinol-binding protein 4 (RBP4), visfatin, chemerin, and adipocyte fatty-acid-binding protein (AFABP) in NAFLD, taken from preclinical to clinical studies, is overviewed. The effect of therapeutic interventions on adipokines' circulating levels are also covered. Finally, future directions to address the potential of adipokines as therapeutic targets and disease biomarkers for NAFLD are discussed.
Datos de la publicación
- ISSN/ISSNe:
- 2079-7737, 2079-7737
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 36009862
BIOLOGY-BASEL Multidisciplinary Digital Publishing Institute (MDPI)
Citas Recibidas en Web of Science: 49
Documentos
Filiaciones
Keywords
- NAFLD; adipokines; biomarkers; clinical trials; fibrosis; inflammation; liver; preclinical studies; steatosis; therapy
Financiación
Proyectos y Estudios Clínicos
'Una aproximación translacional desde la clínica a la experimentación animal: Estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a desórdenes metabólicos. -
Investigador Principal: MARIA JESUS SANZ FERRANDO
PROMETEO2019/032 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO . 2020
CONTRATOS MIGUEL SERVET
Investigador Principal: VERA LUCÍA GOMES FRANCISCO
CP21/00025 . INSTITUTO SALUD CARLOS III . 2022
Cita
Francisco V,Sanz MJ,Real JT,Marques P,Capuozzo M,Ait D,Gualillo O. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?. Biology-Basel. 2022. 11. (8):1237. IF:4,200. (2).
Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?. Francisco V, Sanz MJ, Real JT, Marques P, Capuozzo M, Ait D, Gualillo O. BIOLOGY-BASEL. 2022 agosto 19. 11 (8):DOI:10.3390/biology11081237. PMID:36009862.
